Influential cancer group rolls out first set of 'affordability' ratings on cancer drugs

The National Comprehensive Cancer Network unveiled its first set of "evidence blocks" that include cost information on oncology drugs; this first round focuses on chronic myelogenous leukemia (CML) and multiple myeloma. Drugs from Bristol-Myers Squibb ($BMY), Novartis ($NVS), Johnson & Johnson ($JNJ), and Celgene ($CELG), among others, were assessed on efficacy, safety and affordability. More from FiercePharmaMarketing

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.